Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a simple text reminder help catch lung cancer early?

NCT ID NCT05952778

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more people get potentially life-saving screening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
reminder messages
What this could lead to
If successful, this could point toward a simple, low-cost way to boost lung cancer screening rates in people at risk.
What could go wrong
This is a small, early-stage study focused on measuring acceptability, not actual screening uptake. The reminders may not change behavior in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

133 people

The number who actually took part.

Started

Jun 2023

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

M D Anderson Cancer Center

Ages

40 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults ages 40-80 years * Currently use combustible tobacco products or used combustible tobacco products in the past * English or Spanish speaker (based on self-report) Or an adult caregiver/care partner or family member of someone with a history of combustible tobacco product use (may participate in focus groups, cognitive interviews, surveys) Exclusion Criteria: • History of lung cancer (based on self-report)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.